François Franceschi has worked at GARDP since April 2018 and has over 30 years of experience in the area of antimicrobials.
Prior to working with GARDP, François served as Program Officer for Therapeutics Development (antibacterial and antifungal) at the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, where he also served as NIAID’s liaison to CARB-X and as a member of its Scientific and Milestone Review Boards. From 2002 to 2012, he held various Director positions in Antibiotic R&D at Rib-X Pharmaceuticals (now Melinta Therapeutics) in New Haven, Connecticut. From 1990 until 2002 François was Principal Investigator at the Max Planck Institute for Molekulare Genetik in Berlin, Germany, where his research was devoted to the structure and function of ribosomes, especially in complex with antibiotics. His group at the MPI was a pivotal part of an international consortium headed by Ada Yonath, the winner of the Nobel Prize in Chemistry in 2009.
François earned a PhD in Chemistry at the Frei Universität Berlin, and his undergraduate degree in Biology at Universidad Simon Bolívar in Venezuela.